Exploring the link between MORF4L1 and risk of breast cancer - PubMed (original) (raw)

Christopher M Maxwell, Emiko Tominaga, Montserrat Porta-de-la-Riva, Núria Bonifaci, Laia Gómez-Baldó, Massimo Bogliolo, Conxi Lázaro, Ignacio Blanco, Joan Brunet, Helena Aguilar, Juana Fernández-Rodríguez, Sheila Seal, Anthony Renwick, Nazneen Rahman, Julia Kühl, Kornelia Neveling, Detlev Schindler, María J Ramírez, María Castellà, Gonzalo Hernández; EMBRACE; Douglas F Easton, Susan Peock, Margaret Cook, Clare T Oliver, Debra Frost, Radka Platte, D Gareth Evans, Fiona Lalloo, Rosalind Eeles, Louise Izatt, Carol Chu, Rosemarie Davidson, Kai-Ren Ong, Jackie Cook, Fiona Douglas, Shirley Hodgson, Carole Brewer, Patrick J Morrison, Mary Porteous, Paolo Peterlongo, Siranoush Manoukian, Bernard Peissel, Daniela Zaffaroni, Gaia Roversi, Monica Barile, Alessandra Viel, Barbara Pasini, Laura Ottini, Anna Laura Putignano, Antonella Savarese, Loris Bernard, Paolo Radice, Sue Healey, Amanda Spurdle, Xiaoqing Chen, Jonathan Beesley; kConFab; Matti A Rookus, Senno Verhoef, Madeleine A Tilanus-Linthorst, Maaike P Vreeswijk, Christi J Asperen, Danielle Bodmer, Margreet G E M Ausems, Theo A van Os, Marinus J Blok, Hanne E J Meijers-Heijboer, Frans B L Hogervorst; HEBON; David E Goldgar, Saundra Buys, Esther M John, Alexander Miron, Melissa Southey, Mary B Daly; BCFR; SWE-BRCA; Katja Harbst, Ake Borg, Johanna Rantala, Gisela Barbany-Bustinza, Hans Ehrencrona, Marie Stenmark-Askmalm, Bella Kaufman, Yael Laitman, Roni Milgrom, Eitan Friedman, Susan M Domchek, Katherine L Nathanson, Timothy R Rebbeck, Oskar Thor Johannsson, Fergus J Couch, Xianshu Wang, Zachary Fredericksen, Daniel Cuadras, Víctor Moreno, Friederike K Pientka, Reinhard Depping, Trinidad Caldés, Ana Osorio, Javier Benítez, Juan Bueren, Tuomas Heikkinen, Heli Nevanlinna, Ute Hamann, Diana Torres, Maria Adelaide Caligo, Andrew K Godwin, Evgeny N Imyanitov, Ramunas Janavicius; GEMO Study Collaborators; Olga M Sinilnikova, Dominique Stoppa-Lyonnet, Sylvie Mazoyer, Carole Verny-Pierre, Laurent Castera, Antoine de Pauw, Yves-Jean Bignon, Nancy Uhrhammer, Jean-Philippe Peyrat, Philippe Vennin, Sandra Fert Ferrer, Marie-Agnès Collonge-Rame, Isabelle Mortemousque, Lesley McGuffog, Georgia Chenevix-Trench, Olivia M Pereira-Smith, Antonis C Antoniou, Julián Cerón, Kaoru Tominaga, Jordi Surrallés, Miguel Angel Pujana

Affiliations

Griselda Martrat et al. Breast Cancer Res. 2011.

Abstract

Introduction: Proteins encoded by Fanconi anemia (FA) and/or breast cancer (BrCa) susceptibility genes cooperate in a common DNA damage repair signaling pathway. To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens.

Methods: Protein physical interactions were screened using the yeast two-hybrid system. Co-affinity purifications and endogenous co-immunoprecipitation assays were performed to corroborate interactions. Biochemical and functional assays in human, mouse and Caenorhabditis elegans models were carried out to characterize pathway components. Thirteen FANCD2-monoubiquitinylation-positive FA cell lines excluded for genetic defects in the downstream pathway components and 300 familial BrCa patients negative for BRCA1/2 mutations were analyzed for genetic mutations. Common genetic variants were genotyped in 9,573 BRCA1/2 mutation carriers for associations with BrCa risk.

Results: A previously identified co-purifying protein with PALB2 was identified, MRG15 (MORF4L1 gene). Results in human, mouse and C. elegans models delineate molecular and functional relationships with BRCA2, PALB2, RAD51 and RPA1 that suggest a role for MRG15 in the repair of DNA double-strand breaks. Mrg15-deficient murine embryonic fibroblasts showed moderate sensitivity to γ-irradiation relative to controls and reduced formation of Rad51 nuclear foci. Examination of mutants of MRG15 and BRCA2 C. elegans orthologs revealed phenocopy by accumulation of RPA-1 (human RPA1) nuclear foci and aberrant chromosomal compactions in meiotic cells. However, no alterations or mutations were identified for MRG15/MORF4L1 in unclassified FA patients and BrCa familial cases. Finally, no significant associations between common MORF4L1 variants and BrCa risk for BRCA1 or BRCA2 mutation carriers were identified: rs7164529, Ptrend = 0.45 and 0.05, P2df = 0.51 and 0.14, respectively; and rs10519219, Ptrend = 0.92 and 0.72, P2df = 0.76 and 0.07, respectively.

Conclusions: While the present study expands on the role of MRG15 in the control of genomic stability, weak associations cannot be ruled out for potential low-penetrance variants at MORF4L1 and BrCa risk among BRCA2 mutation carriers.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Mrg15 deficiency confers sensitivity to γ-radiation. Mrg15-null murine embryonic fibroblasts (MEFs) show intermediate sensitivity to γ-radiation relative to controls (WT, wild-type; _Morf4l1_-/-, Mrg15-deficient; and _Atm_-/-, Atm-deficient). *Significant differences between WT and _Morf4l1_-/- MEFs (one-tailed t test, P < 0.01).

Figure 2

Figure 2

Mrg15 deficiency impairs Rad51 foci formation and reduces Brca1 and Brca2 levels. (a) Left panel: number of cells with Rad51 nuclear foci (>4 foci per nuclei) in wild-type and _Morf4l1_-/- murine embryonic fibroblast (MEF) clones after (16 hours) treatment with 10 Gy. **Significant difference (two-tailed t test, P < 0.001). Right panel: representative images of Rad51 and pS139-H2ax immunodetection in cultures counted above for foci. DAPI, 4,6-diamidino-2-phenylindole; IR, γ-irradiated. (b) Levels of Brca1, Brca2 and Rad51, and control Actb, in whole cell extracts of _Morf4l1_-/- MEFs and wild-type counterparts (three cell clones of each genotype are shown).

Figure 3

Figure 3

Phenotypic study of Caenorhabditis elegans brc-2 and mrg-1 mutants. (a) Representative images of meiotic cells at the distal part, near the gonad bend. RAD-51 foci are bright and nuclear in wild-type (WT) animals whereas RAD-51 foci appear less intense and weakly diffuse in the cytoplasm, reduced but often dispersed and intense in the nuclei, or absent in brc-2, mrg-1 and rad-51 mutants, respectively. There are more RPA-1 nuclear foci in each of the three mutants than in WT animals. 4,6-Diamidino-2-phenylindole (DAPI) panels are merged with the red channel (for WT and brc-2 mutant) and with the green channel (for rad-51 mutant). *Abnormal chromosomal compaction. (b) Quantitation of RAD-51 and RPA-1 foci per nuclei in several germ cell lines of WT animals and brc-2 and mrg-1 mutant animals. Number of cells scored (n) and standard deviation of the mean indicated. **Significant differences relative to WT (Mann-Whitney U test, P < 0.001). (c) SYTO-12 staining in synchronized adult worms. Left top panel: an animal heterozygous for the brc-2 mutation (according to green fluorescent protein expression at the pharynx) shows WT SYTO-12 staining (that is, one to two labeled cells at the gonad bend). Right top and left bottom panels: an increase in SYTO-12-positive cells in the germline of brc-2 and mrg-1 mutants, respectively. Right bottom panel: magnification of the highlighted area in the left panel.

Figure 4

Figure 4

Variation at the MORF4L1 locus and breast cancer risk. (a) SNPs with previous suggestive evidence of association with breast cancer (BrCa) risk in the general population (_P_2df < 0.01) [67], genes and the linkage disequilibrium structure around MORF4L1 in HapMap Caucasians (data release 27). (b) Hazard ratio (HR) estimates of association of rs7164529 (top panels) and rs10519219 (bottom panels) with BrCa risk among BRCA1 (left panels) and BRCA2 (right panels) mutation carriers. Graphs show HRs and 95% confidence intervals of heterozygotes and minor allele homozygotes for all participating centers except for rs10519219 and relatively small groups (less than five individuals with the minor genotype). Size of the rectangle is proportional to the corresponding study precision.

References

    1. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8:735–748. -PubMed
    1. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med. 2010;362:1909–1919. doi: 10.1056/NEJMra0809889. -DOI -PMC -PubMed
    1. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42:410–414. doi: 10.1038/ng.569. -DOI -PubMed
    1. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010;42:406–409. doi: 10.1038/ng.570. -DOI -PubMed
    1. Crossan GP, van der Weyden L, Rosado IV, Langevin F, Gaillard PH, McIntyre RE, Gallagher F, Kettunen MI, Lewis DY, Brindle K, Arends MJ, Adams DJ, Patel KJ. Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet. 2011;43:147–152. doi: 10.1038/ng.752. -DOI -PMC -PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources